Schwarz Pharma Submits NDA and MAA Applications for Rotigotine Patch Called Neupro™ for the Treatment of Early Parkinson’s Disease
Aderis Pharmaceuticals partner, Schwarz Pharma, announces that New Drug Application (NDA) and Marketing Authorization Application (MAA) for NeuproTM (rotigotine transdermal system) to treat Parkinson’s disease submitted to the U.S. and the European regulatory authorities for review.
Hopkinton, MA - Sep 29, 2004 - Aderis Pharmaceuticals partner, Schwarz Pharma, reports that applications for marketing approval for the rotigotine transdermal system, a patch, to treat patients in early stages of Parkinson's disease have been submitted to both, the European Medicines Agency (EMEA) and the U.S. Food and Drug Administration (FDA).
"At Aderis, we are excited about the progress of our product candidates and their potential ability to improve quality of life for millions of people. We are committed to helping patients and investors understand our progress as we achieve corporate and clinical milestones."
-Kenneth L. Rice, Jr.,
Chief Commercial Officer, Aderis Pharmaceuticals
back to top
